Table 1. Studies describing the use of high-dose intravenous methylprednisolone in allergic bronchopulmonary aspergillosis

Fist author [ref.]	Patients	Age years	M/F	Risk factor	Mean serum IgE IU·mL⁻¹	Methylprednisolone dose	Steroid duration	Outcomes	Side-effects
Thomson [9]	4	6.075 (1.7–8.2)	3/1	CF	2950.5	20 mg·kg⁻¹ every 4 weeks	4 years	3 out of 4 patients had clinical stabilisation	Hypertension and hyperglycaemia in one patient each
Cohen-Cymberknoh [10]	9	17.1 (7–36)	4/5	CF	542	10–15 mg·kg⁻¹ (max 1 g) every 4 weeks	6–10 months	Significant improvement in FEV₁ and decreased IgE in all cases	Weight gain and psychiatric disorder in one patient each
Thomas [11]	1	11	1/0	CF	9178	20 mg·kg⁻¹ for 3 days followed by 10 mg·kg⁻¹ for 3 days	6 days	Clinical stabilisation
Skov [12]	25	19.9 (10–34)	16/9	CF	NA	15 mg·kg⁻¹	3–7 months	Clinical stabilisation; reduction in the number of exacerbations	Minimal side-effects

Data are presented as n or mean (range), unless otherwise stated. M: males; F: females; CF: cystic fibrosis; NA: not available; FEV₁: forced expiratory volume in 1 s.